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Nancy F. Krebs10, Shivaprasad Goudar11, Richard J. Derman12, Fabian Esamai13, Edward A. Liechty14,
Nellie I. Hansen2, Sreelatha Meleth2, Dennis D. Wallace2, Marion Koso-Thomas15, Alan H. Jobe16,
Pierre M. Buekens17 and José M. Belizán1

Abstract
Background: The Antenatal Corticosteroid Trial assessed the feasibility, effectiveness, and safety of a multifaceted
intervention to increase the use of antenatal corticosteroids (ACS) in mothers at risk of preterm birth at all levels of
care in low and middle-income countries. The intervention effectively increased the use of ACS but was associated
with an overall increase in neonatal deaths. We aimed to explore plausible pathways through which this intervention
increased neonatal mortality.
Methods: We conducted a series of secondary analyses to assess whether ACS or other components of the multifaceted
intervention that might have affected the quality of care contributed to the increased mortality observed: 1) we
compared the proportion of neonatal deaths receiving ACS between the intervention and control groups; 2) we
compared the antenatal and delivery care process in all births between groups; 3) we compared the rates of possible
severe bacterial infection between groups; and 4) we compared the frequency of factors related to ACS administration
or maternal high risk conditions at administration between the babies who died and those who survived 28 days
among all births in the intervention group identified as high risk for preterm birth and received ACS.
Results: The ACS exposure among the infants who died up to 28 days was 29 % in the intervention group compared to
6 % in controls. No substantial differences were observed in antenatal and delivery care process between groups. The
risk of pSBI plus neonatal death was significantly increased in intervention clusters compared to controls (2.4 % vs. 2.0 %,
adjusted RR 1.17, 95 % CI 1.04–1.30, p = 0.008], primarily for infants with birth weight at or above the 25th percentile.
Regarding factors related to ACS administration, term infants who died were more likely to have mothers who received
ACS within 7 days of delivery compared to those who survived 28 days (26.5 % vs 17.9 %, p = 0.014), and their mothers
were more likely to have been identified as high risk for hypertension and less likely for signs of preterm labor.
Conclusions: These results suggest that ACS more than other components of the intervention may have contributed to
the overall increased neonatal mortality. ACS may have also been involved in the observed increased risk of neonatal
infection and death. Further trials are urgently needed to clarify the effectiveness and safety of ACS on neonatal health
in low resource settings.
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Background
Preterm birth remains a leading cause of child mortality
and morbidity [1]. To reduce neonatal mortality associated with preterm birth, antenatal corticosteroids (ACS)
for pregnant women at high risk of preterm delivery is
among the most effective hospital-based interventions in
high resource settings [1–7]. Currently, less than 10 %
and less than 50 % of women at risk of preterm delivery
in low income countries and middle income countries,
respectively, receive ACS [5, 8]. Scaling up ACS has been
a priority for some international health organizations
[9, 10]. To that purpose, the Eunice Kennedy Shriver
National Institute of Child Health and Human Development (NICHD)’s Global Network for Women and
Children’s Health Research Antenatal Corticosteroids
Trial (ACT) [11, 12] assessed the feasibility, effectiveness, and safety of a complex intervention to increase
the use of ACS at all levels of care at seven study
sites in low and middle-income countries (LMIC)
(Argentina, Guatemala, Kenya, Zambia, Pakistan and
India [2 sites]). Because the gestational age data in
those settings was unreliable, we elected to define the
target group as those pregnancies delivering an infant
at a weight below the site-specific 5th percentile.
Overall, the intervention effectively increased the use
of ACS among women who delivered infants with a
birthweight below the 5th percentile. Forty-five percent
of <5th percentile births in the intervention group compared to 10 % in the control group received at least
one dose of ACS (p < 0.0001). Of all women who received antenatal corticosteroids in the intervention
group, 976 (16 %) of 6109 had delivered a less-than5th-percentile infant. However, the intervention did
not significantly reduce neonatal mortality for infants
with birthweight <5th percentile and was associated
with an overall increase in neonatal deaths by 3.5 per
1000 livebirths in the intervention compared to the
control group [12]. This harmful effect on neonatal
mortality was observed among infants with a birthweight greater than the 25th percentile. The intervention was also associated with a significant increase of
suspected infection in the women (2.5 % intervention
vs. 1.7 % in controls, p < 0.0001).
The ACT results raised questions about pathways
through which the intervention may have increased neonatal mortality in the general population of the intervention group. The trial was pragmatic in design, with
limited data collection beyond study outcomes. The
intervention was multifaceted, including training on
identification of women at risk for preterm birth as well
as ACS administration, the ability to identify the causal
pathways of the increased mortality is limited. Nevertheless, because ACT is the largest trial of ACS in LMICs
to date and because of the unanticipated results, we
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conducted a series of post-hoc secondary analyses to explore the trial outcomes further.
The aim of these secondary analyses was to explore
plausible pathways through which the multifaceted intervention might increase neonatal mortality in the overall
populations of the intervention group compared to the
control group.

Methods
Study design and participants

ACT was an 18-month, two-arm, parallel, clusterrandomised trial to assess the feasibility, effectiveness,
and safety of a multifaceted intervention designed to increase the use of antenatal corticosteroids at all levels of
health care in low-income and middle-income countries.
The trial methods and results are described in detail
elsewhere [11, 12]. Briefly, we randomly assigned rural
and semi-urban clusters within six countries (Argentina,
Guatemala, Kenya, Zambia, Pakistan and India [2 sites])
to standard care or a multifaceted intervention including
components to improve identification of women at risk
of preterm birth, referral for care, and to facilitate appropriate use of antenatal corticosteroids. The primary outcome was 28-day neonatal mortality among infants less
than the 5th percentile for birthweight (defined by sitespecific data as a proxy for preterm birth). Additionally,
use of antenatal corticosteroids, neonatal and perinatal
mortality, and suspected maternal infection were measured for all births, irrespective of birthweight.
The outcome data were collected independently by
trained Registry Administrators in a prospective maternal and newborn health (MNH) registry [13, 14], which
enrolled and collected outcomes for all pregnant women
residing within the study clusters, defined geographic
areas which included health facilities. In addition, in
the ACT intervention clusters, process data were collected on the use of ACS and the characteristics of the
eligible women. The trial period included births between
October 2011 and March 2014, depending on each site’s
18-month enrollment period, with most occurring in 2012
and 2013. Additionally, we included data collected during
the pretrial period for births occurring mainly in 2010,
although the pretrial period included some births in
2011 and 2012 in four clusters in Belgaum that were
added in 2011.
Research questions

1) Were ACS a direct cause of the increased mortality
in the intervention group? The multifaceted
intervention effectively increased the ACS use fourfold in women who delivered <5th-percentile for
birthweight infants (45 % vs 10 %) and six-fold
among all women with livebirths (12 % vs 2 %), in
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intervention compared to control clusters [12].
However other components of the multifaceted
intervention could have played a role in the observed
effects. To strengthen the hypothesis of ACS as the
main cause, an increased use of ACS should be
observed among the neonatal deaths in the
intervention group compared to the control group
as well. To answer this question we compared the
proportion of neonatal deaths receiving ACS
between the intervention and control groups among
all neonatal deaths and in the deaths of babies ≥25th
percentile for birthweight, the group among whom
the increase in mortality was concentrated.
2) Did the ACT intervention affect the quality of care
in the intervention compared to the control group?
An explanation of the increased mortality could be
that the intervention affected the quality of perinatal
care and thereby increased neonatal mortality
[15, 16]. We hypothesized that the harmful effects
could have been mediated or confounded by aspects
of care other than ACS, namely, the process of
antenatal, obstetric and neonatal care. To answer
this we compared the antenatal and delivery care
processes between the intervention and control
groups, taking into consideration pre-trial imbalances.
We have focused on detecting potential clinically
relevant differences in the process of care rates, rather
than statistical differences. With these large numbers,
small and clinically not important differences would
appear as statistically significant, thus we have not
conducted statistical tests for the analysis answering
this question.
3) Did the intervention increase the risk of neonatal
severe infection in the intervention compared to
the control group? One hypothesis was that
infection was the pathway by which neonatal
mortality increased, based on the known
immunosupresor effect of corticosteroids [17]. As
reported in the primary paper, suspected maternal
infection was higher in the ACT intervention arm
[3 %] compared to the control arm [2 %]) [12]. Data
on confirmed maternal or neonatal infection were
not collected for the trial. However, clinical
symptoms data were used to define neonatal
possible severe bacterial infection (pSBI) based on
the World Health Organization Young Infants
Clinical Signs Study criteria [18]. An infant with any
of the following was defined as having pSBI:
breathing difficulty, feeding problems (i.e., stopped
suckling or feeding), high fever (>38 °C),
hypothermia (<35 °C), convulsions, and bleeding
or pus-like discharge from umbilicus. The goal of
this analysis was to compare pSBI rates, and pSBI
plus death rates, in the first 6 weeks of life in
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intervention vs. control groups, adjusting for
pre-trial imbalances.
4) Were factors related to ACS administration (such
as the number of doses and the time between ACS
administration and delivery) or the maternal
conditions at administration associated with
neonatal mortality in the intervention group? In
ACT intervention clusters, health providers were
trained to identify pregnant women before 36 weeks’
gestation at risk of preterm birth (i.e., with signs of
labor, preterm premature rupture of membranes,
pre-eclampsia or eclampsia, or obstetric
hemorrhage) and to administer one course of
dexamethasone every 12 h. The main aim of this
observational analysis was to assess whether factors
related to ACS administration were associated with
neonatal death. To assess this, we compared the
frequency of the factors related to ACS administration
between the neonatal deaths and those who survived
to 28 days, among livebirths whose mothers were
identified as high risk for preterm birth and received
ACS in the intervention clusters. We focused on the
subgroup of term babies (≥37 weeks gestation), as
the harmful effect was primarily in this group, and
to reduce the confounding effect of gestational age
in the comparison between neonatal deaths and
survivors.
The definitions for variables constructed from the
study data forms for these analyses are provided in
Appendix 1. Unless otherwise noted, the remaining
variables are defined as collected on the study forms.
Statistical analyses

Generalized linear models were used to assess differences between groups and to develop point and interval
estimates for relative risk (RR) of the outcome of interest. Models were log binomial when possible; otherwise
Poisson models were utilized. Generalized estimating
equations were used to account for the correlation of
outcomes within cluster to develop appropriate confidence intervals. In general, models included adjustment
for randomization strata except that research site, rather
than strata, was included in models assessing differences
in the intervention group only (research question 4). For
question 3, the proportions of infants with pSBI in
clusters assigned to receive the intervention and in control clusters were compared during the pretrial period
and during the trial period. Relative risks for pSBI during
the trial period were estimated with adjustment for
randomization strata only and again with adjustment for
both strata and the pretrial proportions of pSBI at the
cluster level. All tests were performed at a nominal significance level of α = 0.05. Due to the exploratory nature
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of the analyses, no correction was made for multiple
comparisons. Additional statistical methods are noted
under the results of each question, as needed. Analyses
were done by RTI International with SAS versions 9.3
and 9.4 (SAS Institute, Cary, NC, USA).
Approvals

The ACT trial was reviewed and approved by the ethics
committees at each site, the World Health Organization
and the Eunice Kennedy Shriver National Institute of
Child Health and Human Development (NICHD). An
independent data monitoring committee appointed by
NICHD reviewed the progress of the trial, as specified in
the protocol. All women provided informed consent
prior to enrollment.
Role of the funding source

Staff from the funder (NICHD) had input into study
questions and data interpretation and reviewed and approved the report. However, the authors’ views do not
necessarily represent those of the NICHD. The authors
had access to all the data in the study upon request and
all reviewed and approved the paper prior to submission.

Results
The study populations for each analysis are shown in
Fig. 1. Overall, the population included 48,219 women
and 48,698 babies (47,394 live births) in the ACT intervention group and 51,523 women and 52,007 babies

Fig. 1 Trial profile and analyses
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(50,743 live births) in the control group. At 28 days,
there were 1300 neonatal deaths (27.4/1000 livebirths) in
the intervention group and 1211 (23.9/1000 livebirths)
in the control group. When we limited analyses to the
newborns whose mothers received ACS in the intervention group, the population included 6109 women and
6257 babies (of whom 5971 were livebirths).
Antenatal corticosteroids as a cause of neonatal mortality

The ACS exposure among the infants who died up to
28 days was 29 % in the intervention group compared to
6 % in the control group. Among infants who were
≥25th percentile for birthweight and died up to 28 days,
the ACS exposure was 11 % and 2 % in the intervention
and control groups, respectively.
Did the intervention change the process of care
compared to the control group?

There were no substantial differences in antenatal care
attendance rates between the groups. The proportion of
women screened for syphilis or HIV was also similar
between groups, as were the use of preventive interventions such as tetanus vaccine and prenatal vitamins or
iron (Table 1). Fewer women in the intervention group
were delivered by a physician or in hospital during the
trial period. However, similar differences in delivery location and attendant existed during the pretrial period,
as well. A smaller proportion of women in the intervention group delivered at facilities with C-section
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Table 1 Factors related to process of care by ACT treatment group among all births (SB + LB)
Characteristic

Pretrial

Trial

Treatment

Control

Treatment

Control

30,492

34,533

48,219

51,523

Any antenatal care

28,743 (94.4)

32,801 (95.1)

Number of antenatal visits

Data not collected during pretrial period

Deliveries, N
Antenatal Care

45,374

48,052

0

1216 (2.7)

1111 (2.3)

>3

24,663 (54.4)

25,491 (53.0)

43,980

46,632

1st

22,196 (50.5)

24,801 (53.2)

2nd

14,648 (33.3)

14,059 (30.1)

3rd

7136 (16.2)

7772 (16.7)

Trimester of 1st antenatal visit

Administration of diagnosis tests or preventive care
Syphilis or HIV test

21,944/30,435 (72.1)

24,071/34,446 (69.9)

37,975/47,961 (79.2)

40,343/51,185 (78.8)

Tetanus toxoid vaccine

26,892/30,422 (88.4)

30,467/34,478 (88.4)

40,313/47,980 (84.0)

44,453/51,219 (86.8)

Prenatal vitamin/iron

27,706/30,405 (91.1)

30,829/34,472 (89.4)

44,321/47,952 (92.4)

47,212/51,191 (92.2)

Delivery care
Delivery attendant

30,490

34,531

48,215

51,519

Physician

10,305 (33.8)

12,709 (36.8)

19,122 (39.7)

23,233 (45.1)

Nurse/nurse midwife/LHW

10,348 (33.9)

10,094 (29.2)

18,166 (37.7)

15,366 (29.8)

9837 (32.2)

11,728 (34.0)

10,927 (22.7)

12,920 (25.1)

TBA/Family/Unattended
Delivery location
Hospital

30,482

34,494

48,217

51,519

12,013 (39.4)

15,008 (43.5)

23,798 (49.4)

27,345 (53.1)

Clinic

8486 (27.8)

7619 (22.1)

13,593 (28.2)

11,675 (22.7)

Home/Other

9983 (32.8)

11,867 (34.4)

10,826 (22.5)

12,499 (24.3)

C-section

3001 (9.8)

3279 (9.5)

7133/48,218 (14.8)

7655/51,520 (14.9)

Use of new gloves

28,391/30,240 (93.9)

32,262/34,140 (94.5)

44,932/47,860 (93.9)

48,587/51,095 (95.1)

Use of clean razor

27,685/30,263 (91.5)

31,707/34,181 (92.8)

46,963/47,248 (99.4)

49,846/50,261 (99.2)

Births at facility with c-section capabilities

9122/27,831 (32.8)

10,859/31,783 (34.2)

17,802/43,072 (41.3)

21,038/45,190 (46.6)

Births at facility with C-section and neonatal care capabilitiesa

4134/27,831 (14.9)

4590/31,783 (14.4)

11,138/43,072 (25.9)

12,290/45,190 (27.2)

Babies, N

30,762

34,863

48,698

52,007

Babies receiving resuscitation

1451/30,757 (4.7)

2001/34,861 (5.7)

3429/48,535 (7.1)

3973/51,871 (7.7)

a

Neonatal care capabilities include bag and mask, and oxygen or mechanical ventilation

capabilities. No substantial differences were observed
between the proportions of women in the intervention
and control groups who delivered in facilities with all
care capabilities. Additionally, the mode of delivery
was similar in the groups with 15 % cesarean section
during the trial period. Intervention and control
groups also had similar use of new gloves (approximately 94 %), and a clean razor to cut the umbilical
cord (99 %), as available measures of quality of care.
The proportion of babies that received resuscitation was
slightly lower in the intervention than in the control group
(7.1 % vs 7.7 %), but a similar trend was observed in the
pre-trial period (4.7 % vs 5.7 %).

Did the intervention increase risk of neonatal possible
severe bacterial infection (pSBI)?

During the pretrial period, 12.4 % of live born infants in
the ACT intervention group versus 14.2 % of infants in
control clusters had pSBI (Table 2). Risk of pSBI was not
significantly different for infants during the pretrial
period in intervention versus control clusters overall
[adjusted RR: 0.95 (0.75–1.21), p = 0.68]. Similarly,
during the trial period risk of pSBI was not significantly different for infants in intervention compared
to control clusters overall after adjustment for pretrial
rates [14.8 % vs. 13.9 %, adjusted RR: 1.05 (0.92–1.20), p =
0.44]. Among infants with birth weight <25th percentile,
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Table 2 pSBI and pSBI plus death in the first 6 weeks of life among live born infants in ACT intervention clusters during the pretrial
and trial periods
pSBI
Characteristic
Pretrial, N
pSBI, n (%)
ACT period, N

Intervention

Control

29,783

33,900

3702 (12.4)

4814 (14.2)

Adjusted RR (95 % CI) of pSBI Intervention vs. Adjusted RR (95 % CI) of pSBI Intervention vs.
Controla
Control w/adjustment for pretrial pSBI %a

0.95 (0.75–1.21)

46,688

49,990

6891 (14.8)

6945 (13.9)

1.01 (0.89–1.14)

1.05 (0.92–1.20)

< 25 P

2718/10,479
(25.9)

2818/10,726
(26.3)

0.99 (0.89–1.11)

1.03 (0.92–1.15)

≥ 25th P

4058/36,007
(11.3)

4015/39,030
(10.3)

1.10 (0.95–1.28)

1.15 (0.98–1.35)

Characteristic

Intervention

Control

Adjusted RR (95 % CI) of pSBI & death
Intervention vs. Controla

Adjusted RR (95 % CI) of pSBI & death Intervention
vs. Control w/adjustment for pretrial pSBI %a

Pretrial, Nb

29,780

33,892

Had pSBI and
died, n (%)

681 (2.3)

829 (2.4)

ACT period, N

46,688

49,990

Had pSBI and
died, n (%)

1132 (2.4)

1018 (2.0)

1.16 (1.04–1.29)

1.17 (1.04–1.30)

< 25th Pc

627/10,479
(6.0)

601/10,726
(5.6)

1.02 (0.90–1.16)

1.03 (0.90–1.17)

≥ 25th P

405/36,007
(1.1)

317/39,030
(0.8)

1.36 (1.13–1.64)

1.36 (1.12–1.65)

pSBI, n (%)
th

c

pSBI and Death

0.96 (0.87–1.07)

a
Relative risks and confidence intervals from log binomial or poisson models fit to the binary pSBI or pSBI and death outcome that included effects for
randomization strata and intervention group, with and without adjustment for pretrial pSBI proportions at the cluster level. Relative risks significantly different
from 1.0 are shown in bold
b
11 infants born in the pretrial period who had pSBI and were missing 6 week status were excluded (three intervention, eight control)
c
Birth weight percentile was missing for 436 (0.5 %) infants (intervention: 202, control: 234) with missing measured birth weight

the relative risk during the trial period was similar to that
in the overall population [adjusted RR: 1.03 (0.92–
1.15), p = 0.63]. However, in infants with birth weight
≥25th percentile we observed a marginally significant
15 % increase in the risk of pSBI [adjusted RR: 1.15
(0.98–1.35), p = 0.08].
The risk of pSBI plus neonatal death did not differ significantly during the pretrial period for the intervention
versus control group [2.3 % vs. 2.4 %, adjusted RR: 0.96
(0.87–1.07), p = 0.45]. During the trial period, the risk of
pSBI and death was increased for infants in the intervention compared to control group overall [2.4 % vs. 2.0 %,
adjusted RR: 1.17 (1.04–1.30), p = 0.008]. Similarly,
among infants with birth weight ≥25th percentile risk
of pSBI plus death was increased during the trial
period for infants in the intervention compared to
control group [adjusted RR: 1.36 (1.12–1.65), p =
0.002]. However, among infants with birth weight <25th
percentile, no increased risk of pSBI plus death was
observed in the intervention group [adjusted RR: 1.03
(0.90–1.17), p = 0.67.]

Which factors related to ACS administration were
associated with neonatal deaths?

Factors related to ACS administration in the treatment
group among the infants who died compared to those
who survived to day 28 are shown in Table 3, by term
versus preterm delivery. Overall, infants who died were
more likely to have mothers who received ACS within
7 days of delivery compared to those who survived
28 days (58.2 % vs 32.0 %; p < 0.0001). They were also
more likely to receive fewer doses of dexamethasone;
32.5 % of infants who died received only one dose
compared to 20.9 % in those who survived 28 days.
Regarding the maternal conditions at the time of ACS
administration, those women whose infants died were
less likely to have been identified due to signs of preterm
labor and more likely to have had hypertension or
hemorrhage. Where a woman was identified or received
the first dose did not vary substantially for infants who
died compared to those who survived. In the group of
term babies a similar pattern was observed. Term infants
who died were more likely to have mothers who received
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Table 3 ACS administration characteristics in neonatal deaths <28 days compared to survivors at 28 days by prematurity among
those identified by the intervention who received steroids
Characteristic- n (%)

Women, N
Time since 1st dose to delivery
Less Than 2 Days

Preterm

Totalb

Term

ND
<28d

LB, alive
at 28d

204

1639

203

1633

101 (49.8)

765 (46.8)

Pa

*

ND
< 28d

LB, alive
at 28d

100

3672

98

3597

16 (16.3)

411 (11.4)

Pa

*

ND
< 28d

LB, alive
at 28d

304

5311

301

5230

117 (38.9)

1176 (22.5)

2–7 Days

48 (23.6)

263 (16.1)

10 (10.2)

232 (6.4)

58 (19.3)

495 (9.5)

8–30 Days

26 (12.8)

279 (17.1)

14 (14.3)

808 (22.5)

40 (13.3)

1087 (20.8)

More than 1 month

28 (13.8)

326 (20.0)

58 (59.2)

2146 (59.7)

86 (28.6)

2472 (47.3)

193

1569

99

3626

292

5195

1 dose

82 (42.5)

622 (39.6)

13 (13.1)

464 (12.8)

95 (32.5)

1086 (20.9)

2 doses

16 (8.3)

120 (7.6)

7 (7.1)

141 (3.9)

23 (7.9)

261 (5.0)

3 doses

7 (3.6)

64 (4.1)

0 (0.0)

68 (1.9)

7 (2.4)

132 (2.5)

4 doses

88 (45.6)

763 (48.6)

79 (79.8)

2953 (81.4)

167 (57.2)

3716 (71.5)

Doses of 6 mg Dexamethasone Received

Maternal conditions at moment of receiving corticosteroids

204

1639

Signs of preterm labor

139 (68.1)

1208 (73.7)

PPROM

45 (22.1)

390 (23.8)

Hemorrhage

31 (15.2)

128 (7.8)

Hypertension

32 (15.7)

Other

5 (2.5)

Where was the woman first identified?

*

100

3672

74 (74.0)

2910 (79.2)

*

304

5311

213 (70.1)

4118 (77.5)

16 (16.0)

627 (17.1)

61 (20.1)

1017 (19.1)

4 (4.0)

191 (5.2)

35 (11.5)

319 (6.0)

233 (14.2)

24 (24.0)

531 (14.5)

56 (18.4)

764 (14.4)

39 (2.4)

1 (1.0)

128 (3.5)

6 (2.0)

167 (3.1)

**

**

204

1639

100

3672

304

5311

Community level

109 (53.4)

897 (54.7)

72 (72.0)

2322 (63.2)

181 (59.5)

3219 (60.6)

Primary health care

69 (33.8)

463 (28.2)

22 (22.0)

934 (25.4)

91 (29.9)

1397 (26.3)

Hospital

26 (12.7)

279 (17.0)

6 (6.0)

416 (11.3)

32 (10.5)

695 (13.1)

Where was the injection given, N

204

1639

100

3672

304

5311

204

1639

100

3672

304

5311

Home

32 (15.7)

280 (17.1)

19 (19.0)

820 (22.3)

51 (16.8)

1100 (20.7)

Health Center

139 (68.1)

950 (58.0)

72 (72.0)

2332 (63.5)

211 (69.4)

3282 (61.8)

Hospital

33 (16.2)

409 (25.0)

9 (9.0)

520 (14.2)

42 (13.8)

929 (17.5)

118

974

86

3198

204

4172

Home

31 (26.3)

317 (32.5)

30 (34.9)

1184 (37.0)

61 (29.9)

1501 (36.0)

Health Center

50 (42.4)

401 (41.2)

48 (55.8)

1523 (47.6)

98 (48.0)

1924 (46.1)

Hospital

37 (31.4)

256 (26.3)

8 (9.3)

491 (15.4)

45 (22.1)

747 (17.9)

1st dose

2nd dose

Pa

**

**

*

**

a

P-value for a binary outcome of death are from generalized linear models with generalized estimating equations to estimate parameters while controlling for
cluster correlations. All models are also adjusted for clinical site. In a few instances with small cell counts, p-values are calculated from CMH test adjusted for
clinical site ‘*’ indicates statistical significance between 0.0001 to <0.05. ‘**’ indicates statistical significance <0.0001, and blank indicates non-significance
b
Limited to live births with prematurity status available (5615/6109 (92 %) of women in the intervention group who were identified as high risk for preterm birth
and received steroids)

ACS within 7 days of delivery compared to survivors
(26.5 % vs 17.9 %; p = 0.0140), and were also more likely
to have mothers who had hypertension and less likely
to have mothers who were identified due to signs of
preterm labor, compared to survivors. However there
were no substantial differences in the number of
doses received.

Discussion
In these secondary analyses of the ACT trial, we explored pathways through which the multifaceted intervention may have increased neonatal mortality in the
overall population. First, to determine whether ACS or
other components of the intervention could have been
responsible for the increased neonatal mortality, we
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observed that babies who died in the intervention group
received ACS five times more frequently than those in
the control group. On the other hand, the process of
care was either not clinically different between groups,
or the lower rates of hospital births observed in the
intervention group compared to control group were preexistent. Second, while the 5 % increase observed in risk
of pSBI for infants in the intervention group compared
to control was not statistically significant, risk of pSBI
plus neonatal death was 17 % greater in the intervention
group, a statistically significant increase. Finally, exploring which factors of ACS administration were associated
with neonatal deaths, we observed that 27 % of term
born infants who died received ACS within 7 days of delivery, compared to 18 % of survivors at 28 days. Term
babies who died were also more likely to have had
mothers identified due to hypertension and less likely
due to signs of preterm labor, compared to survivors.
Because this is a secondary analysis of a trial not designed to answer these questions, the results should be
considered with caution, but may suggest further lines of
research.
The difference observed in neonatal deaths receiving
ACS between trial groups, plus the lack of differences in
the antenatal and delivery health care process attributable to other components of the multifaceted intervention, strengthen the potential role of steroids as a direct
cause of the increased mortality. Moreover, the magnitude of the difference (29 % of neonatal deaths with
ACS in intervention vs 6 % in control group) is enough
to account for the 11 % higher neonatal mortality rate
observed in the intervention clusters [12].
Our findings suggest an increased risk of neonatal severe infection associated with the intervention, primarily
for infants with birth weight at or above the 25th percentile. These findings should be interpreted cautiously
because this outcome was defined as a composite of
clinical signs and symptoms reported by health care
workers or family members that has shown a moderate
degree of misclassification [19]. Nevertheless, the results
are consistent with the increase in suspected maternal
post-partum infection reported in the primary trial paper
associated with the multifaceted intervention [12]. Furthermore, the trend observed in increased risk of pSBI
and the stronger significantly increased risk of pSBI plus
death among infants in the intervention group at and
above the 25th percentile for birthweight, are in agreement with the harmful effect on neonatal mortality also
concentrated among those infants reported in the primary
trial paper [12], as well as in term infants. Additionally, a
systematic review of small ACS trials reporting outcomes
in babies who delivered later than 7 days after ACS administration showed a non-significant 59 % increase in the
rates of infant proven infection, however based only on
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one trial [20]. No trials included in the Roberts & Dalziel
2006 Cochrane systematic review reported neonatal infection outcomes in babies born after at least 36 weeks of
gestational age [4]. Although this information is far
from proving a causal association, neonatal infection
should be further investigated as a main outcome in future research studies.
Finally, it is difficult to interpret the observed associations between a shorter time period between ACS
administration and delivery and different maternal conditions at identification as high risk patients (more
mothers identified due to hypertension and fewer due to
signs of preterm labor) in those babies who received
ACS and died compared to those receiving ACS and
survived, and should be considered cautiously. First,
residual confounding is a possible explanation of differences of such moderate magnitude. Although we focused on the subgroup of term babies trying to prevent
confounding by gestational age at birth (babies who died
were more likely to be preterm than survivors; and babies born preterm are theoretically more likely to have
shorter time period between ACS administration and
delivery), differences in gestational age between deaths
and survivors are still likely among the babies at term.
Unfortunately, the poor gestational age ascertainment at
the sites precluded stratification by weeks of gestational
age. Second, we would have expected that the time
period had been longer and not shorter in the deaths
than in survivors, based on the observed harmful effect
on neonatal mortality concentrated among ≥25th percentile and term babies [12]. Nevertheless, while ACS
are not associated with a change in the latency period
prior to preterm delivery in high resource environments, the co-morbidities of nutritional deficiencies
and pregnancy abnormalities unique to low resource
environments could have resulted in the unanticipated
outcomes.

Conclusions
In summary, these secondary analyses suggest that ACS
more than other components of the multifaceted intervention may have been involved in the observed increased neonatal mortality, and also in the observed
increased risks of potential severe infections reported in
this paper. No clear interpretations can be drawn about
the characteristics of ACS administration that could
have been associated with a higher risk of neonatal
death. These interpretations should be considered cautiously and no practical implications can be derived from
them. However, they support that further trials are urgently needed to clarify the effectiveness and safety of
ACS on neonatal health in low resource settings, and
that neonatal infection should be included as a main
outcome in such trials.
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Appendix

Table 4 Variable definitions
Variable

Definition and Notes

<5th percentile for birthweight status

The less-than-5th-percentile birthweight group (referred to as less-than-5th-percentile infants)
was a proxy for preterm birth and, in view of the differences in birthweight distributions across
the sites, was established separately for each site on the basis of birthweight data for the pretrial
year. Site-specific cutoffs were 2450 g for Argentina, 2400 g for Zambia, 2267 g for Guatemala,
2000 g for Belgaum, India, 2150 g for Pakistan, 2000 g for Nagpur, India, and 2500 g for
Kenya. Infants were classified as less than 5th percentile on the basis of measured birthweights.
Estimated weights by clinical assessment were used when measured weights were unavailable;
those missing both estimated and measured weights were classified as less than 5th percentile
(since based on historical data, most of the missing data were for preterm infants).

<25th percentile for birthweight status

We limited this variable to those with measured birthweight. Those with only estimated
birthweight or missing birthweight were excluded. We used site-specific cut offs for the 25th
percentile for birthweight.

Preterm/term

The baby’s preterm birth status was calculated using gestational age from last menstrual period
and estimated due date. Additionally, we classified or reclassified those with measured birth
weight (regardless when measured) greater than or equal to the 95th percentile for weight at
36 weeks gestational age (using site-specific cut offs using WHO weight percentiles calculator
that gives gestational age specific distributions http://www.who.int/reproductivehealth/topics/
best_practices/weight_percentiles_calculator.xls)) and less than 5500 g as term. 4292 (7 %) of
births were coded on weight alone and did not have a GA based on EDD or LMP. This variable
resulted in a preterm birth percentage of 11 % of the total population (10 % of live births).

Gestational age band

Beginning with the preterm variable above, we coded the gestational age bands. We first
determined whether the gestational age was “well dated”. Pregnancies dated from the actual
date of delivery, with a date that is unknown/estimated or without a method recorded for
determining the delivery date were considered not well dated. Pregnancies dated from LMP,
clinical exam, USG were considered well dated. If the method of obtaining the delivery date was
based solely on LMP, then we kept the gestational age from LMP. Otherwise, if the method was
clinical exam or USG, or a combination of LMP and one of these, then we kept the gestational
age from EDD.

Suspected maternal infection

Composite of process outcomes including receipt of antibiotics plus hospital admission or
referral, and one or more of the following: receipt of intravenous fluids, surgery, or other
treatment related to infection. Additionally, women with postpartum signs and symptoms of
severe sepsis with admission to hospital or sepsis as the primary cause of maternal death were
included. The definition also included evidence of antepartum or post-partum infection for
mothers with infants with a birthweight less than 2500 g. Antepartum infection was defined as:
Antepartum hyperthermia ≥38 °C AND (Chorioamnionitis OR Purulent amniotic fluid) OR Postpartum
Infection was defined as: Sepsis postpartum OR (postpartum hyperthermia ≥38 °C AND Antibiotics
IM or IV AND at least one of the following: surgery site Infection, foul smelling lochia OR
any postpartum intervention (Hysterectomy, Curettage/MVA/Evacuation, blood transfusion)).

Neonatal possible severe bacterial infection (pSBI)

Neonatal symptoms occurring during the first 6 weeks of life and reported in the GN Maternal
and Newborn Health (MNH) Registry were used to derive estimates of possible severe bacterial
infection (pSBI) based on the WHO Young Infants Clinical Signs Study criteria [Young Infants
Clinical Signs Study Group 2008] to the extent possible given the information recorded in the
registry. The presence or absence of each of the following symptoms was recorded in the
registry, with a “yes” response considered consistent with pSBI: breathing problems/difficulty
breathing, feeding problems/stopped suckling/feeding, high fever (>38 °C), hypothermia (<35 °C),
convulsions, and bleeding/pus-like discharge from umbilicus. Infants who died with cause of
death coded “infection” were also counted as having pSBI. Additionally, text fields used to record
information about symptoms and diagnoses as well as cause of death were reviewed. Infants
with any of the symptoms listed above, or infection, sepsis, possible sepsis, septic conditions (eg,
septic rash, septic cord), meningitis, and/or pneumonia in any of the text fields were counted as
having pSBI. The number of pSBI episodes and the exact timing of infection could not be
determined, as dates of diagnosis were not recorded.
Two of the 63,685 livebirths in the ACT pretrial period are missing pSBI status: one infant with
neonatal outcome coded as born alive but cause of death indicated fetal demise (Guatemala,
control) and one infant with missing delivery date (Pakistan, intervention). Of the 98,137 livebirths
in the trial period, 1459 (1.5 %) are missing pSBI status (intervention: 706, control: 753). The
majority (1454) were 2013 births in Pakistan with some or all data collected on revised forms that
did not include the symptom questions used to define pSBI. Three other infants with neonatal
outcome coded as born alive but with cause of death recorded as fetal demise or macerated
stillbirth are missing pSBI status (one from Nagpur, two from Guatemala) and two others from
Kenya.
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Table 4 Variable definitions (Continued)
Some limitations of this definition include the following, We were unable to match YICSS
symptoms completely. Some symptoms, especially breathing problems, were non-specific, as
they overlap with viruses, malaria, prematurity, etc. There was a lack of confirmatory tests such as
blood cultures or chest x-rays and possibly reporting differences between sites.
Location of delivery by availability of delivery and
neonatal care at the facility

We limited the data to births that either occurred at home or at a facility that is generally used
by the women living in the MNH clusters. This included facilities that are physically located
within the geographic boundaries of the clusters and facilities that are outside the cluster, but
are regularly utilized by the women. For each facility, we determined whether or not each of the
following services had been provided to at least two people during the course of the trial: c-section,
bag and mask, and oxygen or mechanical ventilation. If so, then the facility was coded as having the
service. If not, the facility was coded as not having the service. We could then determine whether
each birth occurred at a facility with these services available. The variable has the following levels:
• Home birth
• Delivered at hospital or clinic with none of the maternal/neonatal capabilities
• Delivered at hospital or clinic with some, but not all maternal/neonatal capabilities
• Delivered at hospital or clinic with all maternal/neonatal capabilities
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